Cyanocobalamin

證據等級: L5

預測適應症: 1 個

Cyanocobalamin: From Vitamin B12 Supplementation to Biotin Metabolic Disease

One-Sentence Summary

Cyanocobalamin (vitamin B12) is an essential micronutrient used to treat vitamin B12 deficiency and pernicious anaemia. The TxGNN model predicts it may be effective for Biotin Metabolic Disease, but the evidence is weak — all 15 clinical trials retrieved are only tangentially related (Grade C relevance), and the 20 publications discuss general B-vitamin metabolism rather than direct therapeutic evidence. This prediction likely reflects pathway proximity in the knowledge graph rather than genuine therapeutic potential.

Quick Overview

Item	Content
Original Indication	Vitamin B12 deficiency, pernicious anaemia (no SAHPRA registrations on file)
Predicted New Indication	Biotin Metabolic Disease
TxGNN Prediction Score	99.60%
Evidence Level	L5 — Model prediction only, no direct clinical studies
South Africa Market Status	Not registered
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacology, cyanocobalamin (vitamin B12) is a water-soluble vitamin that serves as a cofactor for two key enzymes: methionine synthase (which converts homocysteine to methionine) and methylmalonyl-CoA mutase (which converts methylmalonyl-CoA to succinyl-CoA in the propionate metabolism pathway).

The mechanistic link to biotin metabolic disease lies in the propionate metabolism pathway: biotin-dependent propionyl-CoA carboxylase acts upstream (converting propionyl-CoA to methylmalonyl-CoA), while B12-dependent methylmalonyl-CoA mutase acts immediately downstream (converting methylmalonyl-CoA to succinyl-CoA). Both vitamins are essential for sequential steps in the same metabolic cascade. However, this is a sequential dependency, not functional redundancy — B12 cannot compensate for the loss of biotin-dependent carboxylase function. A patient with biotinidase deficiency or holocarboxylase synthetase deficiency requires biotin itself, not B12.

The high TxGNN score (99.60%) most likely reflects the topological proximity of cyanocobalamin and biotin metabolic disease nodes in the knowledge graph, owing to shared pathway annotations, co-occurrence in metabolic disease literature, and overlapping patient populations (e.g., organic acidaemias). This does not translate to therapeutic substitutability. The score should therefore be interpreted with considerable caution.

Clinical Trial Evidence

All 15 retrieved clinical trials received a Grade C relevance rating — none directly test cyanocobalamin as a treatment for biotin metabolic disease. The most pathway-relevant trials are listed below:

Trial Number	Phase	Status	Enrolment	Key Findings
NCT02426775	Phase 3	Completed	33	Carglumic acid (Carbaglu) in propionic acidaemia and methylmalonic acidaemia — related metabolic pathway but evaluates a different drug
NCT05687474	N/A	Completed	6,824	Universal genomic newborn screening for 126 treatable genetic diseases including inborn errors of metabolism — screening study, not therapeutic intervention
NCT05832190	N/A	Terminated	5	Fibre and biotin supplementation to improve gut microbiota post-bariatric surgery — terminated early with only 5 participants enrolled
NCT03655223	N/A	Enrolling by invitation	30,000	Early Check newborn screening programme for rare conditions — epidemiological, not interventional
NCT04312152	N/A	Unknown	200	Metabolic support therapy (Q10 + vitamins B and E) in autism — status unknown, different indication
NCT01173315	Phase 2	Completed	75	Vitamins and minerals for diabetic neuropathy/nephropathy — different indication entirely
NCT00572741	N/A	Completed	39	Nutritional intervention targeting oxidative stress in autism — tangential metabolic overlap only

Summary: No clinical trial directly evaluates cyanocobalamin for the treatment of biotin metabolic disease. The retrieved trials involve multi-vitamin supplementation in unrelated conditions or screening programmes.

Literature Evidence

Of 20 publications retrieved, none report clinical evidence of cyanocobalamin treating biotin metabolic disease. The most relevant publications discussing the shared metabolic pathways are:

PMID	Year	Type	Journal	Key Findings
23622402	2013	Review	Handbook of Clinical Neurology	Comprehensive review of vitamin-responsive disorders including cobalamin, folate, and biotin — describes distinct inborn errors requiring specific cofactors, not interchangeability
38203763	2024	Review	Int J Mol Sci	B12 deficiency and the nervous system — notes B12 role in succinyl-CoA synthesis from methylmalonyl-CoA and biotin, but focuses on B12-specific neuronal mechanisms
1909779	1991	Observational	Pediatric Research	In vivo propionate metabolism in patients with propionic acidaemia, methylmalonic acidaemia, and multiple carboxylase deficiency — demonstrates distinct biochemical defects requiring specific cofactors
7027768	1981	Review	Acta Vitaminol Enzymol	Vitamins in metabolic diseases — reviews vitamin malabsorption, errors in vitamin metabolism, and vitamin-dependent syndromes; each vitamin treats its own dependent pathway
958746	1976	Review	Pediatr Clin North Am	Megavitamin-responsive aminoacidopathies — B-complex cofactors activate specific apoenzymes; therapeutic trials are specific to each vitamin
7015958	1980	Review	Ann NY Acad Sci	Interactions of B-complex vitamins in metabolic and catabolic reactions — describes interdependencies but not therapeutic substitutability
6152513	1983	Review	Adv Clin Chem	Vitamin-responsive inborn errors of metabolism — catalogues distinct vitamin-responsive conditions
25388747	2015	Review	Endocr Metab Immune Disord Drug Targets	Vitamins and type 2 diabetes — discusses biotin and B12 roles separately in glucose metabolism
29173522	2017	Review	Gastroenterol Clin North Am	Vitamins and minerals in inflammatory bowel disease — discusses micronutrient deficiencies in IBD, not biotin metabolic disease
36476407	2023	Observational	J Endocrinol	B12 deficiency induces glucose intolerance in rats — preclinical animal study unrelated to biotin metabolic disease

Summary: The literature consistently describes cobalamin and biotin as cofactors for distinct enzymes in a shared pathway. No publication supports the use of cyanocobalamin as a treatment for biotin metabolic disease.

South Africa Market Information

Cyanocobalamin does not currently have any SAHPRA registrations reflected in this evidence pack. However, cyanocobalamin products (vitamin B12 injections and oral supplements) are widely available internationally. Healthcare professionals should consult the SAHPRA database directly for the most current registration status of cyanocobalamin-containing products in South Africa.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Note: Cyanocobalamin is generally well-tolerated as a water-soluble vitamin. Known safety considerations from international references include rare hypersensitivity reactions and the potential for polycythaemia vera exacerbation. However, the formal SAHPRA PI should be consulted for the authoritative safety profile applicable in South Africa.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN prediction score is high (99.60%), but this almost certainly reflects topological proximity in the knowledge graph rather than genuine therapeutic potential. Cyanocobalamin and biotin operate on sequential but distinct enzymatic steps in the propionate pathway — B12 cannot substitute for biotin function. All 15 clinical trials are Grade C relevance, and none of the 20 publications support this repurposing hypothesis. The evidence level is L5 (model prediction only), and the mechanistic rationale argues against rather than for this indication.

To proceed, the following would be needed:

Preclinical evidence demonstrating that cyanocobalamin supplementation improves outcomes in biotin-deficient models (currently absent and mechanistically implausible)
Clarification of SAHPRA registration status for cyanocobalamin products in South Africa
Identification of any specific subgroup of biotin metabolic disease patients with concurrent B12 deficiency who might benefit from combined supplementation
Expert consultation with a metabolic medicine specialist to evaluate whether any niche clinical scenario could justify further investigation

Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing candidates require clinical validation before any therapeutic application. Report adverse drug reactions to SAHPRA.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.